I think the problem is that, even with the companies own forecasts they do not end up cashflow neutral in Q4 without some serious cost cutting and with the latest capital raise it seems that they won't be cutting costs anytime soon.
The only reason I think of where we might see some cost cuts is the removal of Immunotherapies from the books, but I don't know what the quarterly costs of that company is atm.
I have the following numbers for Q4
Adapt Revenue = 6.2M
Infusions Revenue = 4.3M
Manufacturing/Op Cost = 3.8M (@63% GM)
That leaves 6.7M for staff costs, admin costs, marketing, research which I have costing 8.4m over the quarter. So the question is, where does the extra 1.7m come from?
I think the problem is that, even with the companies own...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.30 |
Change
0.300(1.67%) |
Mkt cap ! $351.7M | |||
| Open | High | Low | Value | Volume |
| $18.25 | $18.30 | $18.01 | $12.33K | 679 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $18.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.30 | 247 | 2 |
View Market Depth
| Last trade - 14.56pm 04/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |